Shares of Edwards Lifesciences Corp. (NYSE:EW) saw an uptick in trading volume on Thursday . 2,287,881 shares traded hands during mid-day trading, an increase of 57% from the previous session’s volume of 1,455,487 shares.The stock last traded at $114.95 and had previously closed at $112.71.

A number of brokerages have issued reports on EW. JMP Securities reissued a “mkt perform” rating on shares of Edwards Lifesciences Corp. in a report on Wednesday, June 1st. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 price target (up previously from $110.00) on shares of Edwards Lifesciences Corp. in a research note on Wednesday, April 27th. Canaccord Genuity restated a “buy” rating and issued a $132.00 price target on shares of Edwards Lifesciences Corp. in a research note on Wednesday, June 1st. Leerink Swann restated a “buy” rating and issued a $125.00 price target (up previously from $115.00) on shares of Edwards Lifesciences Corp. in a research note on Wednesday, April 27th. Finally, Citigroup Inc. raised their price target on shares of Edwards Lifesciences Corp. from $86.00 to $94.00 and gave the company a “sell” rating in a research note on Wednesday, July 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $118.13.

The stock’s 50 day moving average is $109.57 and its 200-day moving average is $99.30. The firm has a market capitalization of $25.13 billion and a price-to-earnings ratio of 48.79.

Edwards Lifesciences Corp. (NYSE:EW) last issued its earnings results on Tuesday, July 26th. The medical research company reported $0.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.70 by $0.06. The firm earned $759.30 million during the quarter, compared to the consensus estimate of $724.26 million. During the same period in the previous year, the company posted $0.57 EPS. The firm’s revenue for the quarter was up 23.1% on a year-over-year basis. On average, equities research analysts forecast that Edwards Lifesciences Corp. will post $2.87 earnings per share for the current year.

In related news, Director Steven R. Loranger acquired 5,000 shares of the stock in a transaction dated Tuesday, May 24th. The stock was bought at an average price of $101.07 per share, with a total value of $505,350.00. Following the completion of the transaction, the director now directly owns 1,941 shares of the company’s stock, valued at $196,176.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Huimin Wang sold 13,650 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $98.44, for a total transaction of $1,343,706.00. The disclosure for this sale can be found here.

Other large investors recently modified their holdings of the company. Birch Hill Investment Advisors LLC boosted its position in shares of Edwards Lifesciences Corp. by 86.3% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 299,002 shares of the medical research company’s stock valued at $23,615,000 after buying an additional 138,539 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Edwards Lifesciences Corp. by 113.0% in the fourth quarter. Principal Financial Group Inc. now owns 355,581 shares of the medical research company’s stock valued at $28,083,000 after buying an additional 188,663 shares during the last quarter. Suntrust Banks Inc. boosted its position in shares of Edwards Lifesciences Corp. by 126.2% in the fourth quarter. Suntrust Banks Inc. now owns 19,421 shares of the medical research company’s stock valued at $1,533,000 after buying an additional 10,835 shares during the last quarter. State of Tennessee Treasury Department boosted its position in shares of Edwards Lifesciences Corp. by 47.3% in the fourth quarter. State of Tennessee Treasury Department now owns 90,877 shares of the medical research company’s stock valued at $7,178,000 after buying an additional 29,177 shares during the last quarter. Finally, KBC Group NV boosted its position in shares of Edwards Lifesciences Corp. by 279.9% in the fourth quarter. KBC Group NV now owns 130,931 shares of the medical research company’s stock valued at $10,341,000 after buying an additional 96,462 shares during the last quarter.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.